Upload Image (Max 20MB per Image)
Imprimis Pharmaceuticals has received approval from the Institutional Review Board (IRB) to initiate Phase III clinical trial protocol of its new topical non-steroidal anti-inflammatory drug (NSAID) candidate, Impracor. Impracor is based ...
Tags: Drug Formulation Impracor, Medicine